Otonomy to Report Second Quarter 2021 Financial Results and Provide Corporate Update

Rhea-AI Summary

Otonomy, Inc. (OTIC) will announce its second-quarter 2021 financial results and provide a corporate update on August 4, 2021, at 4:30 p.m. ET. Investors can access the live call by dialing (877) 305-6769 for domestic and (678) 562-4239 for international callers, using conference ID 8157418. The call will be available as a live webcast on the company's investor relations website. Otonomy is focused on developing innovative therapeutics for neurotology, especially addressing hearing loss and tinnitus through its unique drug delivery technology.

Positive

• Upcoming announcement of Q2 2021 financial results and corporate update may provide insights into business performance.
• Continued focus on innovative therapeutics for hearing loss and tinnitus, potentially expanding market opportunities.

Negative

• None.

SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2021 and provide a corporate update at 4:30 p.m. ET (1:30 p.m. PT) on August 4, 2021.

The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 8157418. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.otonomy.com.

About Otonomy

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs with a focus on hearing loss and tinnitus. For additional information, please visit www.otonomy.com.

Contacts:

Media Inquiries:
Spectrum Science
Chloé-Anne Ramsey
Vice President
404.865.3601
cramsey@spectrumscience.com

Investor Inquiries:
Westwicke ICR
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com

FAQ

When will Otonomy report its Q2 2021 financial results?

Otonomy will report its Q2 2021 financial results on August 4, 2021, at 4:30 p.m. ET.

How can I access the Otonomy financial results call?

You can access the call by dialing (877) 305-6769 for domestic or (678) 562-4239 for international callers, using conference ID 8157418.

What is Otonomy's focus in the biopharmaceutical industry?

Otonomy focuses on developing innovative therapeutics for neurotology, particularly targeting hearing loss and tinnitus.